Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michiel Strijbos

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Genome Medicine|November 22, 2018
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesisMarkus Mayrhofer, Bram De Laere, Tom Whitington, et al.
European Urology Oncology|April 22, 2025
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform TrialAlessio Crippa, Bram De Laere, Andrea Discacciati, et al.
The Lancet. Oncology|March 1, 2023
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortiumStephanie G C Kroeze, Matea Pavic, Karin Stellamans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2018
<i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate CancerBram De Laere, Steffi Oeyen, Markus Mayrhofer, et al.
ESMO Open|March 4, 2017
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)Gilberto Morgan, Matteo Lambertini, Hampig Raphael Kourie, et al.
Nature Medicine|August 20, 2024
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trialBram De Laere, Alessio Crippa, Andrea Discacciati, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Genome Medicine|November 22, 2018
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesisMarkus Mayrhofer, Bram De Laere, Tom Whitington, et al.
European Urology Oncology|April 22, 2025
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform TrialAlessio Crippa, Bram De Laere, Andrea Discacciati, et al.
The Lancet. Oncology|March 1, 2023
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortiumStephanie G C Kroeze, Matea Pavic, Karin Stellamans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2018
<i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate CancerBram De Laere, Steffi Oeyen, Markus Mayrhofer, et al.
ESMO Open|March 4, 2017
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)Gilberto Morgan, Matteo Lambertini, Hampig Raphael Kourie, et al.
Nature Medicine|August 20, 2024
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trialBram De Laere, Alessio Crippa, Andrea Discacciati, et al.
Pageof 2